Shimojilide (1), a new cyclic lipopeptide, was isolated from a marine cyanobacterium Okeania sp. Its structure was elucidated by NMR and chemical derivatization, revealing a peptide-polyketide hybrid with a skipped diene and β-branched methyl group. Shimojilide (1) exhibited potent and selective antiproliferative activity with a unique JFCR39 fingerprint that poorly correlates with those of known anticancer agents, suggesting a distinct mechanism of action. Shimojilide (1) represents a promising lead for anticancer drug discovery.
Niiyama et al. (Tue,) studied this question.